
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **May 2, 2003**

000-19319

(Commission File Number)

Vertex Pharmaceuticals Incorporated

(Exact name of registrant as specified in its charter)

MASSACHUSETTS

(state or other jurisdiction of incorporation)

04-3039129

(IRS Employer Identification No.)

130 WAVERLY STREET CAMBRIDGE, MA

(Address of principal executive offices)

02139

(Zip Code)

Registrant's telephone number, including area code: **(617) 444-6100**

ITEM 5. OTHER EVENTS.

On May 2, 2003, Joshua S. Boger, the Company's Chairman and CEO, entered into a plan with Goldman, Sachs & Co., pursuant to which Goldman will undertake to sell, subject to a limit order, an aggregate of 470,000 shares of the Company's stock issuable upon exercise of options held by Dr. Boger. Sales under the plan are to begin no earlier than 90 days after adoption of the plan, and will take place at specified intervals between August 5, 2003 and March 9, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)

Date: May 2, 2003

/s/ Ian F. Smith

Ian F. Smith

Vice President and Chief Financial Officer